Recursion Pharmaceuticals, Inc. (RXRX) Stock Price & Analysis
Recursion Pharmaceuticals, Inc. (RXRX) fell 3.01% to USD 3.22 as of June 9, 2026 at 23:57 UTC, according to Nexqual real-time market data.
RXRX last closed at USD 3.32; the session ranged USD 3.13–3.49 on volume of 17,740,346 shares. Market capitalization is $1.71B, with a 52-week range of USD 2.77–7.18 (NMS). Source: Nexqual, June 9, 2026 at 23:57 UTC.
Key Statistics (as of June 9, 2026 at 23:57 UTC)
| Price | USD 3.22 |
|---|---|
| Change | ▼ 3.01% (down) |
| Previous Close | USD 3.32 |
| Open | USD 3.33 |
| Day Range | USD 3.13 – 3.49 |
| 52-Week Range | USD 2.77 – 7.18 |
| Volume | 17,740,346 shares |
| Market Cap | $1.71B |
| Exchange | NMS |
Technical Analysis (RXRX)
Nexqual's technical model rates RXRX "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:57 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 45.2 (neutral) |
| vs SMA50 | Below (USD 3.33) |
| MACD | 0.04 (positive) |
Analyst Ratings (RXRX)
Wall Street analysts rate RXRX "None" based on 7 analysts, with a mean price target of USD 6.64 (range USD 3–10), per Nexqual as of June 9, 2026 at 23:57 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 6.64 |
| High Target | USD 10 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 3 / 5 / 0 |
Earnings (RXRX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $13.17M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.22 vs est -0.26 ▲ beat |
| 2025-12-31 | USD -0.21 vs est -0.32 ▲ beat |
| 2025-09-30 | USD -0.36 vs est -0.38 ▲ beat |
| 2025-06-30 | USD -0.41 vs est -0.35 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Financials & Fundamentals (RXRX)
| Total Revenue | $66.41M |
|---|---|
| Revenue Growth (YoY) | -56.10% |
| Gross Margin | +0.00% |
| Operating Margin | -1985.55% |
| Profit Margin | +0.00% |
| ROE | -57.16% |
| Debt / Equity | 7.06 |
| Current Ratio | 5.47 |
| Total Cash | $654.47M |
| Total Debt | $72.38M |
| Free Cash Flow | $-177.80M |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Financial Health Score (RXRX)
Nexqual rates Recursion Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:57 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $654M cash vs $72M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$178M, burning cash |
| Efficiency | Critical — ROE -57%, ROA -27.7% |
Ownership (RXRX)
| Insider Ownership | +2.26% |
|---|---|
| Institutional Ownership | +68.75% |
| Shares Outstanding | 524.68M |
| Float | 513.08M |
| Short % of Float | +36.84% |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
Leadership (RXRX)
Recursion Pharmaceuticals, Inc. is led by Najat Khan (age 41), CEO, President & Director, per Nexqual as of June 9, 2026 at 23:57 UTC.
| CEO, President & Director | Najat Khan (age 41) |
|---|---|
| Co-Founder, Chairman & Interim Executive Advisor | Christopher C. Gibson (age 42) |
| CFO & President of Recursion UK | Ben R. Taylor (age 48) |
| Chief Operating Officer | Kristen Rushton |
| Chief Technology Officer | Benjamin Mabey M.S. (age 42) |
Major Backers & Investors (RXRX)
Notable institutional backers of Recursion Pharmaceuticals, Inc. include ARK Invest, Baillie Gifford, Softbank Group Corporation, according to Nexqual as of June 9, 2026 at 23:57 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 14.13% |
| Baillie Gifford | 4.51% |
| Softbank Group Corporation | 2.6% |
| MIC Capital Management UK LLP | 1.84% |
| Goldman Sachs | 1.16% |
| Fidelity | 0.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.05% |
| BlackRock | 10.98% |
| State Street | 9% |
| Geode Capital | 2.34% |
Source: Nexqual, June 9, 2026 at 23:57 UTC.
From Recursion Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
- Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.
- The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TEM | Tempus AI, Inc. | USD 48.82 | ▲ 5.15% |
| SOUN | SoundHound AI, Inc. | USD 7.02 | ▼ 5.01% |
| SERV | Serve Robotics Inc. | USD 6.94 | ▼ 10.45% |
| APLD | Applied Digital Corporation | USD 41.91 | ▲ 5.78% |
| BBAI | BigBear.ai, Inc. | USD 3.99 | ▼ 5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:57 UTC. This page is informational and not investment advice.